Esomeprazole News and Research

RSS

Esomeprazole is a drug that blocks acid from being made in the stomach. It is used to treat acid reflux disease and to prevent certain types of gastrointestinal ulcers. Esomeprazole magnesium is being studied in the prevention of esophageal cancer and in the treatment of other conditions, including side effects of chemotherapy. It is a type of anti-ulcer agent. Also called esomeprazole and Nexium.

Study links acid-reducing drugs to increased risk of migraine

People who take acid-reducing drugs may have a higher risk of migraine and other severe headache than people who do not take these medications, according to a study published in the April 24, 2024, online issue of Neurology Clinical Practice, an official journal of the American Academy of Neurology.

24 Apr 2024

Study challenges link between proton pump inhibitors and kidney disease risk

A study in Scientific Reports investigates the association between proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RA) use on chronic kidney disease (CKD) risk.

5 Dec 2023

Pro-inflammatory cytokine levels and their relation to preeclampsia severity

Researchers examine plasma interleukin-6, vascular cell adhesion molecule-1, and C-reactive protein levels in pregnant women with preeclampsia.

20 Jul 2023

The efficacy of clarithromycin versus levofoxacin-based regimens for H.pylori treatment in naïve patients after the COVID-19 pandemic misuse of antibiotics

Researchers explored the eradication rates of Helicobacter pylori utilizing levofloxacin and clarithromycin-based regimens in patients with prior COVID-19 therapy.

25 Jan 2023

Common heart burn medication could lessen the effectiveness of lung cancer treatment

A common medication used to treat reflux, heart burn and ulcers could lessen the effectiveness of lung cancer immunotherapy drugs, according to new Flinders University research.

24 Nov 2021

Researchers describe a simple, inexpensive way to measure drug dissolution

When you take a time-release drug, you count on it doing what the package says: release the drug slowly into your bloodstream to provide benefits over the specified period of time.

25 Nov 2020

Small molecule drugs binding Mac1 domain of SARS-CoV-2

Now, an intriguing new study out of the University of Wisconsin-Milwaukee reveals that numerous small molecule drugs like the proton pump inhibitors omeprazole and rabeprazole bind the important Mac1 domain on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.

8 Jul 2020

Study shows how long-term use of acid suppressants could increase risk of dementia

Millions of people around the world use acid suppressants called proton pump inhibitors for conditions like heartburn, gastritis and stomach ulcers. Researchers at Karolinska Institutet in Sweden now report that how the long-term use of these drugs could increase the risk of developing dementia.

8 May 2020

$Acid reflux drugs may lead to increased risk of fractures in children$

Acid reflux drugs may lead to increased risk of fractures in children

Proton pump inhibitors - a widely used class of drugs used to treat acid reflux and related symptoms - may lead to an increased risk of fractures in children and adolescents, reports a study in the Journal of Pediatric Gastroenterology and Nutrition.

17 Mar 2020

Gastroesophageal reflux disease may affect nearly a third of U.S. adults every week

Gastroesophageal reflux disease (GERD), a digestive disorder that causes hearburn and other uncomfortable symptoms, may affect nearly a third of U.S. adults each week, and most of those who take certain popular medications for it still have symptoms, according to a new Cedars-Sinai study.

19 Dec 2019

Popular heartburn drug voluntarily recalled for carcinogen levels above FDA standards

The popular heartburn drug ranitidine, commonly known as Zantac, was voluntarily recalled due to the contamination of a human carcinogen that could potentially cause cancer. The recall includes oral tablets, capsules, and syrup.

27 Nov 2019

Common medications to treat heartburn linked to increased risks for kidney failure

Common medications prescribed to treat heartburn, acid reflux and ulcers are linked to increased risks for kidney failure and chronic kidney disease, found a recent University at Buffalo study.

19 Mar 2019

Esophageal cancer risk could be reduced by esomeprazole and low dose aspirin

According to the results of a phase III trial presented at the 2018 ASCO Annual Meeting, two simple over-the-counter medicines – high dose esomeprazole and low dose aspirin when taken regularly can moderately lessen the risk of high grade esophageal cancer in patients who are diagnosed with Barrett’s esophagus when taken for at least 7 years.

5 Jun 2018

Study investigates use of drugs for the stomach and risk of major depressive disorder

A new study investigating the relationship between one of the commonest type of drugs used for protecting the stomach is presented in the current issue of Psychotherapy and Psychosomatics.

8 Mar 2018

Proton pump inhibitors linked to increased death risk

Proton pump inhibitors (PPIs) are one of the commonest agents prescribed for heart burn or acid reflux. These agents are available for purchase over-the-counter making them one of the most commonly used drugs that make around $10 billion in annual sales. PPIs work by reducing the production of the gastric acids in the stomach. There are several known risks associated with PPI use including complete stoppage of gastric acid production, risk of pneumonia, kidney disorders, bone fractures such as hip fractures etc.

5 Jul 2017

Chronic use of antacid drugs may speed up aging of blood vessels

Chronic use of some drugs for heartburn and gastroesophageal reflux (GERD) speeds up the aging of blood vessels, according to a published paper in Circulation Research, an American Heart Association journal.

11 May 2016

Acid suppression drugs frequently prescribed for high-risk newborns, study shows

Since 2006, several published studies have associated the use of some acid suppression medications in hospitalized high-risk babies with infections, necrotizing enterocolitis and increased risk of death. Those medications - histamine-2 receptor antagonists, such as ranitidine (Zantac and others), and proton pump inhibitors, such as esomeprazole (Nexium and others) - were originally approved by the U.S. Food and Drug Administration for use in adults and older children.

27 Apr 2016

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Synthetic Biologics, Inc.), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, announced positive topline results from the first Phase 2a study of SYN-004, the Company's candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD).

1 Dec 2015

Camber Pharmaceuticals releases generic version of Nexium (Esomeprazole) capsules

Camber Pharmaceuticals is pleased to announce that it has launched Esomeprazole Magnesium Delayed-Release Capsules, 20 mg and 40 mg, which is the generic version of Nexium (Esomeprazole) capsules from AstraZeneca Pharmaceuticals. The product is indicated for the treatment of heartburn, gastroesophageal reflux disease (GERD), stomach ulcers, and for a damaged esophagus.

24 Sep 2015

Mylan announces launch of Esomeprazole Magnesium Delayed-release Capsules USP in U.S.

Mylan N.V. today announced the U.S. launch of Esomeprazole Magnesium Delayed-release Capsules USP, 20 mg and 40 mg, which is the generic version of AstraZeneca's Nexium.

6 Aug 2015